According to the research report titled ‘Global Peptide Therapeutics Market (2021 Edition) - Analysis By Drug Type (Generic, Innovative), Manufacturing Type (In-House, Outsourced), Application,, By Region, By Country: Market Insights, Covid-19 Impact, Competition and Forecast (2021-2026)’, available with MarketStudyReport, global peptide therapeutics market was worth USD 32.1 billion in 2020 and is anticipate to grow considerably through 2026.
 

As per the report findings, the expansion of global peptide therapeutics market is attributed to increasing healthcare expenditure, rising prevalence of cancer, and surging geriatric population.
 

Request sample copy of this report:  https://www.marketstudyreport.com/request-a-sample/4226455/
 

Also, soaring number of approved peptide-based therapeutic drugs, growing occurrence of metabolic disorders, and collaborations between biotechnology with pharmaceutical companies are impelling the industry scenario.
 

Furthermore, rising popularity of peptide therapies has shifted the healthcare industry's attention from small-molecule-based interventions toward the complex pharmacological interventions. Peptide therapies' effectiveness is defined by clinical benefits such as excellent target selectivity, favorable safety profiles, and low toxicity.
 

According to the report, the industry would see enormous growth potential as a result of drug discovery and new product releases for chronic metabolic illnesses.
 

On the basis of application, worldwide peptide therapeutics market is categorized into metabolic, oncology, gastrointestinal, neurological, cardiovascular, and others. Speaking of drug type, the industry is split into generic, and innovative. In terms of manufacturing scope, the market is divided into outsourced, and in-house. The study includes information on each segment's industry share, as well as their growth rate and revenue contribution over the forecast period.
 

Coming to regional landscape, the lucrative opportunities across America (US, Canada), Europe (France, Italy, Germany, UK), Asia Pacific (Japan, China, India, South Korea), and LAMEA are unveiled in the report through holistic analysis.
 

Novartis International AG, Sanofi S.A., Pfizer Inc., GlaxoSmithKline plc, Eli Lilly and Company, Novo Nordisk A/S, AstraZeneca plc, Amgen Inc., Bristol Myers Squibb, and Takeda Pharmaceutical Company Limited are the key players in worldwide peptide therapeutics industry. These organizations are constantly spending in R&D to introduce new products, as well as forming strategic partnerships and collaborations to boost their market position.